Entecavir: A new nucleoside analog for the treatment of chronic hepatitis B infection

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1745-1757

  Sims, Keri A ^a   Woodland, Abigail M ^a  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Adefovir dipivoxil; Antiviral; Entecavir; Hepatitis B; Lamivudine; Nucleoside

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; TELBIVUDINE; TENOFOVIR DISOPROXIL; THYMOSIN ALPHA1; UNINDEXED DRUG; VALTORCITABINE;

ABDOMINAL PAIN; ALOPECIA; ANOREXIA; ANTIBIOTIC RESISTANCE; ANXIETY DISORDER; AREA UNDER THE CURVE; BILIRUBIN BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL TRIAL; COUGHING; DEPRESSION; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EMBASE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LACTIC ACIDOSIS; LETHARGY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDLINE; MITOCHONDRIAL TOXICITY; MONOTHERAPY; MOOD DISORDER; MOOD SWING; NEPHROTOXICITY; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOSENSITIVITY; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; STEATOSIS; SYSTEMATIC REVIEW; TUBULAR DYSFUNCTION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; GUANINE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE;

EID: 33845369581     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1745     Document Type: Review

References (87)

1. Asian Liver Center at Stanford University. Statistics, 2003. Available from http://livercancer.stanford.edu/index2.asp?lang=eng&page=statistics. Accessed October 10, 2005.
2. World Health Organization. Disease statistics, May 2005. Available from http://www.who.int/healthinfo/statistics/en. Accessed October 7, 2005.
3. Hepatitis B Foundation. Statistics. Available from http://www.hepb.org/ hepb/statistics.htm. Accessed October 7, 2005.
4. Pai MP, Mercier RC, Raebel MA. Viral hepatitis. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach, 9th ed. New York: McGraw-Hill, 2005:742-51.
5. Buccolo LS. Viral hepatitis. Clin Fam Pract 2005;7:105-25.
6. Fung SK, Lok AS. Drug insight: nucleoside and nucleotide analog inhibitors for hepatitis B. Nat Clin Pract Gastroenterol Hepatol 2004;1:90-7.
7. Chan J. Viral hepatitis. In: Schumock G, Brundage D, Chapman M, et al, eds. Pharmacotherapy self-assessment program, 5th ed. Gastroenterology and nutrition. Kansas City, MO: American College of Clinical Pharmacy, 2005:9-13.
8. Lin KW, Kirchner JT. Hepatitis B. Am Fam Physician 2004;69:75-82.
9. Buti M, Esteban R. Drugs in development for hepatitis B. Drugs 2005;65:1451-60.
10. Fatovich G. Natural history of hepatitis B. J Hepatol 2003;39(suppl 1):S50-8.
11. Funk ML, Rosenberg DM, Lok ASF. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002;9:52-61.
12. Lok AS, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. American Association for the Study of Liver Disease, December 2003. Hepatology 2001;34:1225-41.
13. Keefe EB, Dietrich DT, Han SB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 2004;2:87-106.
14. Lau DT, Membreno FE. Antiviral therapy for treatment-naive hepatitis B virus patients. Gastroenterol Clin North Am 2004;33:581-99.
15. Centers for Disease Control and Prevention. Hepatitis B fact sheet. Available from http://www.hivandhepatitis.com/hep_b/treatment.html. Accessed October 8, 2005.
16. Krogsgaard K, Bindslev N, Christensen E, et al. The treatment effect of alpha-interferon in chronic hepatitis B is independent of pre-treatment variables: results based on individual patient data from 10 clinical controlled trials. European concerted action on viral hepatitis (EUROHEP). J Hepatol 1994;21:646-55.
17. Lacy CF, Armstrong LL, Goldman MP, et al. Interferon. In: Lexi-Comp's drug information handbook, 13th ed. Hudson, OH: Lexi-Comp, 2005:811-15.
18. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305.
19. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005;365:123-9.
20. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBe-Ag-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95.
21. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
22. Nunez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 2005;5:374-82.
23. Cooksley WG. Gastroenterology expert column: the role of interferon therapy in hepatitis B. Med Gen Med 2004;6:16-21.
24. Dienstag JL, Schiff ER, Wright TL. A preliminary study of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
25. GlaxoSmithKline. Epivir-HBV (lamivudine) package insert. Research Triangle Park, NC; 2004.
26. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
27. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha-interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 2000;46:562-8.
28. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia hepatitis lamivudine study group. N Engl J Med 1998;339:61-8.
29. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B: lamivudine precore mutant study group. Hepatology 1999;29:889-96.
30. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-6.
31. Liaw YF, Leung NWY, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-80.
32. Chang TT, Lai CL, Liaw YF, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstr]. Antiviral Ther 2000;5(suppl 1):44.
33. Leung NWY, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
34. Tassopoulos NC, Volpes R, Pastore G, et al. Postlamivudine treatment follow-up patients with HBeAg negative chronic hepatitis B [abstr]. J Hepatol 1999;30(suppl 1):117.
35. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
36. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124:105-17.
37. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. Mutation in HBV RNA dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996;24:714-17.
38. Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and safety of 5-years lamivudine treatment of Chinese patients with chronic hepatitis B [abstr]. J Gastroenterol Hepatol 2001;16(suppl 1):A60.
39. Gilead Sciences. Hespera (adefovir dipivoxil) package insert. Foster City, CA; 2006.
40. U.S. Food and Drug Administration. Center for Drug Evaluation and Research, new and generic drug approvals: 1998-2004. Available from www.fda.gov/cder/approval/index.htm. Accessed October 22, 2005.
41. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
42. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:801-7.
43. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstr]. J Hepatol 2003;38:S143.
44. Tanji N, Tanji K, Kambham N, Markowitz GS, Bell A, D'agati VD. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol 2001;32:734-40.
45. Hadziyannis SJ, Tassopoulos NC, Chang TT, et al. Three year study of adefovir dipivoxil demonstrates sustained efficacy in presumed precore mutant chronic hepatitis B (CHB) patients in a long term safety and efficacy study (LTSES) [abstr]. J Hepatol 2004;40:17.
46. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
47. Seifer M, Hamatake RK, Colonno RJ. In vitro inhibition of hepadnavirus polymerase by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-8.
48. Yamanaka G, Wilson T, Innaimo S, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 1999;43:190-3.
49. Gish RG. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Semin Liver Dis 2005;25(suppl 1):29-39.
50. Honkoop P, deMan RA. Entecavir, a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs 2003;12:638-88.
51. Innaimo SF, Siefer M, Bisacchi GS, et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1999;41:1444-8.
52. Perrillo RP. Current treatment of chronic hepatitis B: benefits and limitations. Semin Liver Dis 2005;25:S20-8.
53. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24:3-10.
54. Bristol-Myers Squibb Co. Baraclude (entecavir) package insert. Princeton, NJ; 2005.
55. Yan JH, Bifano M, Xie J, et al. Effects of renal impairment on single-dose pharmacokinetics of entecavir. Presented as a poster at the 40th annual meeting of the European association of the study of the liver. Paris, France, April 13-17, 2005.
56. Bifano M, Yan JH, Xia J, et al. Hepatic impairment does not alter single-dose pharmacokinetics and safety of entecavir. Presented as a poster at the 55th annual meeting of the American association for the study of liver diseases. Boston, MA, October 29-November 2, 2004.
57. Genovesi EV, Lamb L, Medina I, et al. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 1998;42:3209-17.
58. Julander JG, Colonno RJ, Sidwell RW, Morrey JD. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antivir Res 2003;59:155-61.
59. Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother 2002;46:82-8.
60. Colonno RJ, Genovesi EV, Medina I, et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J Infect Dis 2001;184:1236-45.
61. Wu TT, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for RNA synthesis is amplified by an intracellular conversion pathway Virology 1990;175:255-61.
62. Moraleda G, Spautelli J, Aldrich CE, Averett D, Condreay L, Mason W. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis B virus. J Virol 1997;71:9392-9.
63. Delaney W, Miller T, Isom HC. Use of hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2′-3′- dideoxy-3′-thiacytidine on the replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chem 1999;43:2017-26.
64. DeMan RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology 2001;34:578-82.
65. Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002;123:1831-8.
66. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209.
67. Chang TT, Gish R, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
68. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl Med 2006;354:1011-20.
69. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory, HBeAg(+) chronic hepatitis B: results of phase III study ETV-026 [abstr]. Hepatology 2004;40:664A.
70. Peters MG, Hann HWH, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;1261:91-101.
71. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
72. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003;38:1419-27.
73. Bristol-Myers Squibb Co. Data on file. Princeton, NJ; 2005.
74. Colonno RJ, Rose RE, Levine SM, et al. Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II and III studies is only observed in lamivudine refractory patients [abstr]. Hepatology 2004;40:661A.
75. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004;48:3498-507.
76. Colonno RJ, Rose RE, Levine SM, et al. Entecavir (ETV) resistance is not observed in nucleoside naïve subjects and is observed infrequently by week 48 in lamivudine-refractory subjects with chronic HBV infection. Presented as a poster at the 40th annual meeting of the European association of the study of the liver, Paris, France, April 13-17, 2005.
77. Yang H, Qi X, Das K, et al. In vitro characterization and molecular modeling analysis of a novel adefovir resistance mutation rtN236T in the HBV polymerase [abstr]. J Hepatol 2004;40:A383.
78. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601.
79. Mathews G, Bhagani S. The epidemiology and natural history of HIV/HBV and HIV/HCV co-infections. J HIV Ther 2003;8:77-84.
80. Pessoa W, Gazzard B, Huang A, et al. Entecavir in HIV/HBV-co-infected patients: safety and efficacy in a phase II study. Presented as a poster at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005.
81. Sollano J, Schiff E, Carrilho F, et al. Entecavir is well tolerated for treatment of chronic hepatitis B: phase III safety analysis in nucleoside-naïve and lamivudine-refractory patients [abstr]. Hepatology 2004;40:655A.
82. Manns MP, Raptopoulou-Gigi M, Sollano J, et al. Entecavir is well tolerated for the treatment of nucleoside-naïve and lamivudine-refractory chronic hepatitis B patients: phase II/III safety results. Presented as a poster at the 40th annual meeting of the European association of the study of the liver, Paris, France, April 13-17, 2005.
83. Bifano M, Yan JH, Xie J, et al. Lack of pharmacokinetic interaction when entecavir is co-administered with lamivudine, adefovir, or tenofovir. Presented as a poster at the 40th annual meeting of the European association of the study of the liver, Paris France, April 13-17, 2005.
84. Murray L, ed. Red book update. Montvale, NJ: Thompson PDR, 2006;25:20, 38.
85. Murray L, ed. Red book: pharmacy fundamental reference. Montvale, NJ: Thompson PDR, 2005:370, 417, 440, 541.
86. Clinical trials.gov. Clinical trials. Available from www.clinicaltrials. gov. Accessed May 23, 2006.
87. Liver Foundation. Clinical trials. Available from www.liverfoundation. org/db-list/clinicaltrials/1/ascend/ID/Validated. Accessed May 22, 2006.